10 February 2022 Lysarc
Launch of the VERLEN study
VERLEN est une étude qui vise à évaluer l'efficacité d'une nouvelle com...
29 December 2021 Calym
CALYM: strong dynamics engaged with FINDMED
13 December 2021 Lysarc
The 3000th patient included in REALYSA –...
10 December 2021 Lysarc
ASH 2021: LYSA and LYSARC to present their si...
08 December 2021 Calym
AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING...
01 December 2021 Calym
A STRUCTURING INTEGRATING THE ENTIRE VALUE CH...
29 November 2021 Calym
Congratulations to the 2 new winners of the C...
24 November 2021 Calym
ANTICANCER CELL THERAPY GROUP AND INSTITUT CA...
21 November 2021 Lysa
LYSARC – Review of the 2020 Assessment ...
LYSARC - 2020 Review and outlook for 2021
14 November 2021 Lysarc
The 2020 academic clinical research activity ...
04 November 2021 Lysa
American Society of Hematology annual meeting...
03 November 2021 Lysarc
1000 patients included in the DESCAR-T regist...
02 November 2021 Calym
ISSUES IN LYMPHOMA RESEARCH
22 October 2021 Calym
14th edition of the Rendez-vous Carnot
19 October 2021 Lysarc
Cell Therapy Innovation 360°
11 October 2021 Calym
CALYM’s active role in the research eco...
03 October 2021 Calym
With OncoSTARTUPPER, participate in the Oncol...
14 September 2021 Lysa
World Lymphoma Day 2021
08 September 2021 Lysa
LYSA Presentations at the 2021 SFH Congress
26 August 2021 Lysa
6th edition of LYSA days, Rennes 2021
01 June 2021 Lysa
LYSA presentations in June 2021 international...
31 May 2021 Calym
Launch of OncoSTART consortium supporting onc...
27 May 2021 Lysarc
Launch of BiCAR: an unprecedented clinical s...
27 April 2021 Lysarc
2000th patient included in REALYSA – th...
On April 22, 2021, at the University Hospital Center of Lyon Sud, was recru...